First-line Therapy of untreated advanced or metastatic Renal Cell Cancer
Randomized, open, Phase-3 Study of Nivolumab in Combination with
Cabozantinib versus Sunitinib in Participants with previously untreated,
advanced or metastatic Renal Cell Cancer